The Development of a Standardized Ki-67 Assay
Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
Clinical Pearls
Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
- Ki-67 assays are cheaper than molecular tests
- Measuring Ki-67 before treatment and 4-6 weeks into treatment can determine whether or not therapy is working
- In this trial, researchers stained slides in a standardized way and used computer software to analyze them
- Ki-67 measurement with the software was reproducible, though researchers were able to measure Ki-67 in the traditional way if needed
- Further trials are needed to verify this information
<<<
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
